Quote | SciSparc Ltd ADR (OTCMKTS:TRPXY)
Last: | $6.03 |
---|---|
Change Percent: | 0.5% |
Open: | $6 |
Close: | $6.03 |
High: | $6.15 |
Low: | $6 |
Volume: | 53,544 |
Last Trade Date Time: | 02/09/2021 04:55:16 pm |
News | SciSparc Ltd ADR (OTCMKTS:TRPXY)
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate The companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in 2018 and preparations for CannAmide...
SciSparc Initiates Commercial Production of its CannAmide™ Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada PR Newswire TEL AVIV, Israel , Feb. 9, 2021 /PRNewswire/ -- SciSparc Ltd.(formerly ...
Message Board Posts | SciSparc Ltd ADR (OTCMKTS:TRPXY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
SciSparc Ltd ADR Company Name:
TRPXY Stock Symbol:
OTCMKTS Market:
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate The companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in 2018 and preparations for CannAmide...
SciSparc Initiates Commercial Production of its CannAmide™ Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada PR Newswire TEL AVIV, Israel , Feb. 9, 2021 /PRNewswire/ -- SciSparc Ltd.(formerly ...
Therapix Biosciences Announces Name Change to SciSparc Ltd. PR Newswire TEL AVIV, Israel , Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatme...